Which closed-end funds own Ultragenyx Pharmaceutical Inc?
2 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $1.9M. Security type: common equity. Country: United States. CUSIP 90400D108 · ISIN US90400D1081 · ticker RARE.
Holdings are historical filings (report dates Jun 30, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| BMEZ BlackRock Health Sciences Term Trust | Healthcare | 0.14% | $1.5M | 43,975 sh | $1.1B | NAV unavailable | Jun 30, 2026 |
| BME BlackRock Health Sciences Trust | Healthcare | 0.07% | $388K | 11,623 sh | $573M | 3.7% discount | Jun 30, 2026 |
2 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Issuer-level search for “RARE” → · Compare two funds’ portfolios →